Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7201–7250 of 18652
On December 19, 2023, Adam Laponis notified Eargo, Inc. (“Eargo” or the “Company”) that he will step down as Chief Financial Officer and depart Eargo on January 5, 2024.
On December 19, 2023, Eargo appointed Mark Thorpe as Chief Financial Officer, effective January 5, 2024, to succeed Mr. Laponis.
Mr. Karaivanov’s election to the Board is part of the previously announced succession plan in which Mr. Karaivanov will assume the role of President and Chief Executive Officer of the Company and the Bank effective as of January 1, 2024.
effective January 1, 2024, Daniel C. Bartok, will step down from his role as the President and Chief Executive Officer of Forestar Group Inc.
Mr. Cavanagh will succeed Mr. Jeffrey Stoops as President and Chief Executive Officer, effective January 1, 2024.
On December 18, 2023, Selectis Health, Inc., a Utah corporation (the “Company”) appointed Jim Creamer as Interim Chief Financial Officer and Clifford Neuman to its board of directors.
On December 22, 2023, Trulieve Cannabis Corp. (the “Company”) announced the appointment of Wes Getman as the Company’s Chief Financial Officer, effective January 1, 2024.
On December 14, 2023, the Company’s Board of Directors appointed Edward Honour as Chief Executive Officer (CEO)
On December 14, 2023, Erik Nelson resigned chief financial officer and President of the Company. Mr. Nelson remains Corporate Secretary.
(b) Departure of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
Effective as of the Effective Date, Mr. Frakes, Chief Financial Officer of the Company, was appointed as (i) Interim Chief Executive Officer of the Company, replacing Dr. Fisher, and (ii) a member of the Board of Directors of the Company
On December 22, 2023, the Board appointed Ryan Spick to serve as the Company’s Principal Executive Officer and Chief Financial Officer effective as of December 22, 2023.
On December 15, 2023, R. Bryan Riggsbee, Chief Financial Officer and principal financial officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Mr. Riggsbee would step down from such position, effective upon the earlier of (1) the date that a new Chief Financial Officer and principal financial officer commences his or her employment at the Company and (2) January 31, 2024.
On December 15, 2023, the Board appointed Scott J. Leffler (“Mr. Leffler”) as the Company's Chief Financial Officer and principal financial officer, effective as of his first date of employment, January 29, 2024.
Ms. Krezmer’s position changed to President, Chief Executive Officer and Chief Financial Officer
Mr. Bryant, age 65, has been the Company’s Senior Vice President, Chief Financial Officer and Treasurer since June 2006 through his planned retirement effective on December 31, 2023
Mr. Bassell’s tenure as the Company’s Chief Financial Officer (principal financial and accounting officer) will conclude upon the effectiveness of Mr. Giammatteo’s appointment as Chief Financial Officer on January 2, 2024.
appointed Mr. Robb Giammatteo, as Executive Vice President and Chief Financial Officer (principal financial and accounting officer), effective January 2, 2024.
Effective upon the consummation of the Business Combination, the Company entered into an amended and restated employment agreement with Gary Strahan, its Chief Executive Officer, Steve Winch, its President, and Peter Baird, its Chief Financial Officer.
Effective upon the consummation of the Business Combination, the Company entered into an amended and restated employment agreement with Gary Strahan, its Chief Executive Officer, Steve Winch, its President, and Peter Baird, its Chief Financial Officer.
Mr. Tom Brodmerkel has resigned from the Board of Directors and as CFO of Mitesco as of December 15, 2023
Mr. Mack Leath , age 66, will serve as CEO, CFO and Chairman of the Board of Directors.
Mr. Larry Diamond resigned from all positions including the Board of Directors, CEO of Mitesco and all positions related to The Good Clinic, LLC and its sole member Mitesco N.A. LLC as of December 19, 2023, effective December 29, 2023
Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024
succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.
BCB Bancorp, Inc. (the “Company”), and its wholly owned subsidiary BCB Community Bank (the “Bank”), each appointed Michael A. Shriner as its President and Chief Executive Officer, effective January 1, 2024
On December 18, 2023, the Board of Directors (the “Board”) of the Company appointed Norman L. Miller, previously the Interim President and Chief Executive Officer, to the position of President and Chief Executive Officer effective immediately.
the Board promoted Mr. Ghazi, Synopsys’ President and Chief Operating Officer, to the role of President and Chief Executive Officer
On December 21, 2023, C.H. Robinson Worldwide, Inc. (the “Company”) announced that Michael P. Zechmeister will be departing from his position as Chief Financial Officer of the Company.
the Board of Directors of the Company (the “Board”) has appointed Peter M. Carlson to the position of Chief Financial Officer, effective January 3, 2024.
Upon commencement of Mr. Carlson’s employment with the Company, Nils Windler, who has been serving as Chief Financial Officer of the Company since 2021, will remain with the Company to work closely with Mr. Carlson, support an orderly transition of responsibility and provide financial accounting support to the Company.
On December 20, 2023, Dozy Mmobuosi, who accepted the position of Group Interim Co-CEO on September 15, 2023, has temporarily stepped down as Interim Co-Chief Executive Officer and Member of the Board of Directors in connection with an order sought by the Securities & Exchange Commission
The Company’s other interim co-CEO, Mr. Ken Denos, will serve as its interim group CEO until further notice.
David Stack informed the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") that he intended to retire as Chief Executive Officer of the Company and as a member of the Board effective immediately following the appointment of his successor as Chief Executive Officer.
the Board appointed Frank Lee as Chief Executive Officer of the Company and as a member of the Board, effective January 2, 2024.
On December 17, 2023, AgEagle Aerial Systems Inc. (the “Company”) received notice (the “Notice”) from Mr. Barrett Mooney, the Company’s Chief Executive Officer, that he has decided to depart the Company as Chief Executive Officer and Director to pursue another professional opportunity, effective December 31, 2023.
On December 21, 2023, the Company announced the appointment of John J. Quaid to serve as its Executive Vice President and Chief Financial Officer, effective January 1, 2024.
Michael J. Hennigan, who will cease to serve as President of the Company effective January 1, 2024.
the board of directors (the “Board”) of MPLX GP LLC ("MPLX"), the general partner of MPLX LP, appointed C. Kristopher Hagedorn as Executive Vice President and Chief Financial Officer, effective January 1, 2024.
Mr. Hagedorn will succeed John J. Quaid, who will cease to serve as Executive Vice President and Chief Financial Officer of MPLX effective January 1, 2024 to accept a role as Executive Vice President and Chief Financial Officer of Marathon Petroleum Corporation (“MPC”).
On December 15, 2023, Scott J. Leffler notified Clover Health Investments, Corp. (the “Company”) that he will be stepping down as Chief Financial Officer of the Company, including as principal financial officer and principal accounting officer, effective as of January 26, 2024, in order to pursue another professional opportunity.
On December 15, 2023, the Current Arcadium Board appointed Paul W. Graves as Chief Executive Officer and President, Gilberto Antoniazzi as Chief Financial Officer, Vice President and Treasurer, Sara Ponessa as General Counsel, Vice President and Secretary, and Ronald B. Stark as Chief Accounting Officer
On December 15, 2023, the Current Arcadium Board appointed Paul W. Graves as Chief Executive Officer and President, Gilberto Antoniazzi as Chief Financial Officer, Vice President and Treasurer, Sara Ponessa as General Counsel, Vice President and Secretary, and Ronald B. Stark as Chief Accounting Officer
the Company provided Mr. Souki with notice of termination of his employment with the Company “without Cause” (as defined in the Souki Employment Agreement) effective as of December 8, 2023
Ian Shaw as the Company’s Chief Financial Officer
effective as of November 20, 2023, the Board of Directors of the Company (the “ Board ”) appointed: (i) Anthony Clark as the Company’s President and Chief Executive Officer
On December 20, 2023, Dave & Buster's Entertainment, Inc. (the “Company”) issued a press release announcing the retirement of Michael A. Quartieri, Chief Financial Officer and a named executive officer.
On December 19, 2023, Dr. Matthew Angel notified Eterna Therapeutics Inc. (the “Company”) that he was resigning from his position as the Company’s President and Chief Executive Officer, effective on December 31, 2023.
On December 19, 2023, the board of directors (the “Board”) of the Company appointed Sanjeev Luther as the Company’s President and Chief Executive Officer (and principal executive officer), which appointment will become effective on January 1, 2024,
Michael Salvino, who no longer served as the Company’s President and Chief Executive Officer on December 18, 2023.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.